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Abstract: Osteosarcoma is the most common primary bone tumor in childhood and adolescence. The use of combination 
chemotherapy and surgery enables long-term survival in approximately 60-70% of cases. However, the necessity for sur-
gery, the poor prognosis of patients with metastatic or recurrent disease (long-term survival in only about 20% of cases), 
and the lack of establishment of second-line chemotherapy suggest that improvements in chemotherapy are desperately 
needed. Currently, in an effort to extend the protocol with the chemotherapy drugs that already exist, high-dose chemo-
therapy with/without autologous peripheral blood stem cell transplantation, and tumor-targeted drug delivery systems are 
under investigation. Future drug developments will no doubt lie in the direction of immunotherapy and anti-angiogenic 
therapy, as well as the use of cytotoxic drugs. Identifying the genes and signal transduction pathways responsible for the 
development of osteosarcoma or for the occurrence of malignancy in cases of osteosarcoma will undoubtedly lead to the 
identification of pathway-specific agents, or possible gene therapy. Furthermore, as increased light is shed on the charac-
ter of osetoblastic differentiation in osteosarcoma, this will certainly give rise to new treatments utilizing differentiation 
therapy. This article reviews the current status and perspectives regarding the treatment of osteosarcoma in terms of che-
motherapy. 
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INTRODUCTION 
Osteosarcoma is the most common primary bone tumor 
in childhood and adolescence, and in about 80% of cases it 
occurs in the long bones of the limbs. In the other 20% of 
cases, it occurs in the axial skeleton and pelvis [1]. Com-
monly affected bones, in descending order, are the femur 
(40%), the tibia (20%) and humerus (10%) [2]. Osteosar-
coma occurs primarily in the metaphysis of long bones 
around the knee region of the distal femur or proximal tibia. 
Osteosarcoma is highly aggressive and it metastasizes pri-
marily to the lung [3]. The median age of an osteosarcoma 
patient is 16 years, with a male predominance (male/female 
ratio; 1.6:1). The occurrence of osteosarcoma seems to be 
associated with a spurt in growth [4]. The peak incidence 
among female patients has been reported to be a little earlier 
than that among male patients, probably because of the ear-
lier onset of growth spurt at the growth plate [5, 6]. His-
tologically, osteosarcoma is characterized by a proliferation 
of atypical spindle cells. Malignant osteoid formation is di-
agnostic for osteosarcoma. Conventional osteosarcoma is 
classified into osteoblastic, chondroblastic and fibroblastic, 
according to its predominant features [7]. 
Genetic alterations have been reported in osteosarcoma. 
In particular, the tumor-suppressor pathways of p53 and Rb 
(retinoblastoma tumor-suppressor gene) are thought to be 
involved in the pathogenesis of osteosarcoma [8-11]. The 
majority of patients with osteosarcoma have neither a fami- 
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lial background nor a history of radiation exposure. Li-
Fraumeni syndrome (germline deletion in p53) and familial 
retinoblastoma (germline mutations of Rb) are known to be 
risk factors in the development of osteosarcoma [10, 12-15]. 
Even osteosarcoma without such a background has altera-
tions in both the p53 and Rb pathways in the majority of 
cases [7]. p53 is a tumor-suppressor gene and its product 
plays an important role in the cellular response to DNA 
damage [16]. Rb product has a suppressive effect on the cell 
cycle. p53 and Rb are thought to be involved in osteosar-
coma oncogenesis [17-19]. Unbalanced karyotypes and other 
abnormal cellular signaling pathways have also been re-
ported in osteosarcoma cells. Among possible cytogenetic 
alterations, gains in chromosome 1, loss of chromosome 9 
and loss of heterozygosity on several chromosomes are con-
sistently reported [7]. 
Mouse double minute 2 (MDM2) and cyclin-dependent 
kinase 4 (CDK4) genes have been reported to be amplified 
or overexpressed in osteosarcoma, and these genes are 
thought to be involved in the pathogenesis [20, 21]. The 
MDM2 gene product binds and inactivates p53 protein, 
whereas the CDK4 gene product is a cyclin-dependent 
kinase and possibly inactivates Rb function. c-fos is a tran-
scriptional factor and controls cell-cycle progression. c-fos 
plays an important role in osteoblast and chondrocyte differ-
entiation. Amplification or overexpression of the c-fos gene 
has been reported in osteosarcoma cells [22].  
CURRENT CHEMOTHERAPY 
Until the 1970s, osteosarcoma was treated by amputation 
in most cases, or else by radiotherapy. In spite of local con-
trol, most osteosarcoma patients died within a short period Chemotherapy for Osteosarcoma  Reviews on Recent Clinical Trials, 2008, Vol. 3, No. 3    229 
 
because of lung metastasis. The results of surgery alone as a 
treatment of osteosarcoma have not been satisfactory. The 5-
year disease-free survival rate after treatment by surgery 
alone has been reported to be only 12% [3]. Neoadjuvant 
(preoperative) chemotherapy was introduced in 1978 [23]. 
The purposes of neoadjuvant chemotherapy are the destruc-
tion of primary tumor cells and the eradication of microme-
tastasis. Doxorubicin and methotrexate have been applied 
successfully as chemotherapy drugs for the treatment of os-
teosarcoma [24-27]. In the course of a study into osteosar-
coma chemotherapy, vincristine, bleomycin and dactinomy-
cin have all been proven to be ineffective [28, 29]. Subse-
quently, the addition of cisplatin and ifosfamide to doxorubi-
cin and methotrexate has been able to improve clinical re-
sults significantly [30, 31]. The current standard protocol of 
a three-drug chemotherapy regimen using cispatin, doxoru-
bicin and high-dose methotrexate provides about 70% long-
term disease-free survival for osteosarcoma patients without 
metastasis (Fig. 1) [7]. 
The amount of tumor necrosis following preoperative 
chemotherapy has been known to be a reliable prognostic 
factor, enabling the effectiveness of the chemotherapy treat-
ment to be accurately determined [32, 33]. Tumor necrosis is 
usually assessed as follows: Grade I: no necrosis; Grade II: 
necrosis of between 50 and 95%; Grade III: necrosis greater 
than 95 but less than 100%; and Grade IV: total necrosis; 
100% [23]. Patients with tumor necrosis in excess of (>) 
90% are classified as good responders to chemotherapy, 
whereas those whose tumor necrosis is less than (<) 90% are 
classified as poor responders. 
Therapy for Patients with Metastasized Osteosarcoma 
Unfavorable prognosis is associated with tumor location, 
the number and location of the metastases and lack of ade-
quate surgical resection. In particular, the prognosis of os-
teosarcoma patients with metastasis is still poor, with only 
20% achieving a 5-year survival rate [1]. Treatment for pa-
tients with relapsed osteosarcoma following standard chemo-
therapy or for patients with tumors that are unresponsive to 
standard chemotherapy remains challenging. A second-line 
chemotherapy regimen for use when applied standard che-
motherapy fails, has not been widely accepted [34, 35]. 
High-dose ifosfamide could be used for these patients, espe-
cially when ifosfamide has not been applied previously to 
these same patients [36]. High-dose ifosfamide has been 
reported to be effective against recurrent disease, in a com-
parison with the standard dose [37, 38].  
As for the treatment of lung metastases which appear af-
ter the initial diagnosis, surgical resection is usually consid-
ered. Radiotherapy in the lung after the resection of a metas-
tatic lesion is not undertaken in most cases. In general, when 
a solitary metastatic lesion in the lung is detected more than 
24 months after the initial diagnosis, surgical resection and 
close observation are chosen [39, 40], whereas in the case of 
patients with a single site of disease recurrence after a rather 
short relapse-free interval of around less than 24 months, 
systemic chemotherapy together with resection of the lesion 
is beneficial [7].  
New Treatment 
In order to improve the survival of metastatic patients or 
patients classes as poor-responders following the standard 
protocol of a three-drug chemotherapy regimen using cis-
patin, doxorubicin and high-dose methotrexate, several pro-
tocols comprising intensive chemotherapy, such as high-dose 
or prolonged chemotherapy with/without peripheral blood 
stem cell rescue, have been considered, but the benefit of 
these therapies is not conclusive in long-term follow-up [3, 
41, 42]. Improvement in the delivery efficacy of current 
agents may result in improved clinical results. Liposomal 
encapsulation of doxorubicin has been shown to be effective 











Fig. (1). Osteoblastic osteosarcoma. Plain radiograph of a 19-year-old male clearly shows an irregular osteoblastic feature in the medullary 
region of the distal femur with cortical irregularity over the lateral cortex (arrows) (A). After a three-drug chemotherapy regimen made up of 
cispatin, doxorubicin and methotrexate, wide resection was carried out, followed by reconstruction using a Kotz prosthesis (HMRS: How-
medica Modular Reconstruction System) (B). Histological section reveals osteoblastic osteosarcoma clearly demonstrating osteoblastic fea-
tures, comprising irregular immature bone deposition by anaplastic tumor cells (C). 230    Reviews on Recent Clinical Trials, 2008, Vol. 3, No. 3  Sakamoto and Iwamoto 
 
possibility that the resistance to doxorubicin could be over-
come [43]. Furthermore, the efficacy of an aerosolized for-
mulation of cisplatin has been investigated, especially for 
osteosarcoma patients [7]. 
A variety of agents has been investigated for the treat-
ment of osteosarcoma in clinical trials. Studies with mono-
clonal antibodies, such as 8H9, heat-shock protein inhibitors, 
such as 17-N-allylamino-17-demethoxygeldanamycin [17-
AAG], and small molecule inhibitors, such as gefitinib and 
erlotinib, have been undertaken. Antifolate of methotrexate, 
trimetrexate, has been developed for the treatment of me-
thotrexate-resistant osteosarcoma [44]. In addition, a new 
compound, PNU-159548, may have beneficial effects when 
combined with conventional agents [45]. Endostatin is an 
inhibitor of angiogenesis, and was administered in combina-
tion with liposome to experimental animals with osteosar-
coma [46]. Liposomal muramyl tripeptide phosphatidyletha-
nolamine is an activator of monocytes and macrophages and 
induces the secretion of different cytokines (Interleukin 1[IL 
1], IL 6, tumor necrosis factor  [TNF]), and it has been 
tested in clinical studies on osteosarcoma patients [47, 48]. 
Moreover, an immunomodulator of interferon for use as 
maintenance therapy has also been tested [49].  
Identifying the genes and signal transduction pathways 
responsible for the development and malignant behavior in 
osteosarcoma will lead to the discovery of new drugs and 
therapy. It has been suggested that inhibition of the mammal-
ian target of the rapamycin (mTOR) pathway may be effec-
tive in osteosarcoma [50, 51]. Inhibitors of receptor tyrosine 
kinases, including insulin-like growth factor 1 receptor (IGF-
1R) and a platelet-derived growth factor receptor (PDGFR) 
have been investigated and developed for osteosarcoma 
treatment [52-54]. It has been reported that sustained-release 
sandostatin successfully performed the function of reducing 
serum IGF-1 levels [55]. Gene therapy is approaching readi-
ness for clinical studies, and it now offers potentially promis-
ing results. The effectiveness of p53 gene therapy via a trans-
ferring-liposome-p53 complex administered in animal mod-
els has also been reported [56]. 
The receptor activator of nuclear factor-, its ligand and 
the osteoprotegerin (RANK/RANKL/OPG) system is impor-
tant in bone remodeling and metabolism [57, 58]. This 
RANK/RANKL/OPG system possibly plays a role in the 
pathogenesis of osteosarcoma [59, 60], and its interference 
may provide a new therapeutic strategy. Bisphosphonates 
inhibit osteoclast action and the resorption of bone, and it has 
been demonstrated that bisphosphonates inhibit tumor 
growth  in vitro. Moreover, the effect of bisphosphonates 
combined with the standard protocol of cisplatin, doxorubi-
cin and high-dose methotrexate has been investigated for 
osteosarcoma [61-63]. Peroxisome proliferator activated 
receptor (PPAR)/retinoid X receptor (PPAR/RXR) ago-
nists may induce differentiation in osteosarcoma, despite 
critical blocks to the normal bone morphogenetic protein 
(BMP)-regulated pathways. Differentiation therapy in os-
teosarcoma could be used as a new strategy [64]. 
CONCLUSION 
Osteosarcoma is a highly aggressive tumor with a high 
metastasizing potential. There is no established second-line 
chemotherapy, and accordingly, improvements in chemo-
therapy are desperately needed. Using microarray analysis in 
osteosarcoma, it has been demonstrated that a specific ex-
pression signature can differentiate between chemorespon-
sive and chemoresistant tumors [65]. Understanding the mo-
lecular mechanism of osteosarcoma development and malig-
nant behavior will undoubtedly lead to the discovery of new 
chemotherapy agents. 
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